Estal

Quick links to important sections

Estal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estal

Quick Facts

Property Description
Active Ingredients Chlormadinone acetate, Ethinyl Estradiol
Form Oral tablet (film-coated)
Pharmacological Class Combined Hormonal Contraceptive
General Use Pregnancy prevention / Birth control
Origin Synthetic steroidal hormones

Classification and Core Identity of Estal

Estal is formally classified as a Combined Oral Contraceptive (COC), placing it within the broader pharmacological class of Combined Hormonal Contraceptives. The primary function of this medication is providing effective, systemic pregnancy prevention and birth control for women of reproductive age. This combination of Chlormadinone acetate and Ethinyl Estradiol is indicated for use in contraception, providing predictable hormonal control.

Composition and Pharmaceutical Form

The core of Estal’s composition relies on two synthetic steroidal hormones as its active ingredients: the progestogen Chlormadinone acetate and the estrogen Ethinyl Estradiol. The inclusion of Chlormadinone acetate—a derivative known for its anti-androgenic properties—is a differentiating feature of this specific combination. The medication is presented for oral administration as a film-coated tablet and is structurally defined as a monophasic preparation. This means that the amount and ratio of the two active hormonal components remain standardized and consistent across every hormone-containing tablet within the dosing regimen.

Fundamental Action and General Purpose

The general purpose of Estal is accomplished through a fundamental, systemic action on the endocrine system. The active components work together to suppress ovulation—the primary mechanism—by preventing the body from releasing an egg. Furthermore, the combination simultaneously induces secondary anti-conception effects: it alters the cervical mucus to impede sperm movement, and it causes endometrial changes that make the uterine lining less receptive. These mechanisms work collectively to achieve reliable birth control.

What side effects are possible with Estal?

Possible Side Effects and Safety Information

The safety profile for this combined oral contraceptive, containing Chlormadinone acetate and Ethinyl Estradiol (Estal), is formally documented using standardized regulatory classifications for adverse reactions.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their observed incidence in clinical use, as defined in regulatory documents. Reactions classified as Common (1/100 to <1/10) include headache, nausea, depressed mood, breast pain, and weight gain. Uncommon effects (1/1000 to <1/100) include migraine, vomiting, diarrhea, fluid retention, and rash. Rare effects (1/10,000 to < 1/1000) include thromboembolism and hypersensitivity reactions.


Serious Safety Considerations and Class Risks

Estal shares the class risks associated with all combined hormonal contraceptives. The most clinically significant official adverse reactions are Venous Thromboembolism (VTE), such as Deep Vein Thrombosis and Pulmonary Embolism, and Arterial Thromboembolism (ATE), including Myocardial Infarction and Stroke. The official label also lists the potential for hormone-sensitive malignancies, such as liver tumors.


Contextual Safety Patterns and Restrictions

Unscheduled bleeding and spotting are noted to be more likely to occur during the first three months of use. Safety documents explicitly state an increased risk of severe cardiovascular events in smokers over 35 years of age. Furthermore, the medication is officially restricted or contraindicated in the presence of conditions such as a high pre-existing thrombotic risk, a history of severe hepatic disease, or malignant hormone-sensitive tumors.

Overdose and Emergency Response

Estal Overdose and When to Seek Help

Official regulatory sources document the expected profile for an overdose of Estal, a combined hormonal contraceptive. This type of event is generally not classified as life-threatening based on established data. However, immediate professional assessment is required upon suspected ingestion of amounts exceeding the prescribed therapeutic dose.

Documented Manifestations and Required Actions

The most frequently reported clinical manifestations following an overdose include nausea and vomiting. Other documented signs may include headache, emotional changes, breast tenderness, and drowsiness. In females, an overdose often results in withdrawal bleeding or a delayed presentation of heavy vaginal bleeding. Official regulatory guidance also specifically addresses overdose cases resulting from ingestion by children.

In the event of a suspected overdose, it is officially required to seek medical help right away and contact emergency services or a poison control center. Management is determined to be symptomatic and supportive treatment to address the presenting signs, as no specific antidote is known for this combination of hormones. Clinical assessment includes the monitoring of vital signs and continued observation, ensuring the application of supportive measures as defined by official labeling.

Therapeutic Uses of Estal

What Estal Treats: Main Uses and Benefits

The therapeutic applications of Estal center on reproductive health management and dermatological support. As a combined oral contraceptive, it is used to prevent pregnancy and is relevant in addressing other health conditions. This medication is applied across domains where additional symptomatic support is needed, primarily for systemic pregnancy prevention. It is also commonly used to address moderate acne vulgaris and for the management of symptoms related to the menstrual cycle, which may involve pronounced discomfort and blood flow volume.

“The use is considered relevant in contexts involving heightened systemic burden from chronic or recurrent cycle-related symptoms.”


Supportive Relief and Key Benefits

Estal’s primary therapeutic benefit is the management of cyclical patterns, which supports the patient during episodes associated with reproductive planning. For skin health, this medication may assist with managing issues like excessive oiliness and helps address groups of symptoms related to inflammatory states, which contributes to easing the overall symptom load. For menstrual distress, it can support the management of blood flow volume and discomfort, which helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Androgen-Related Symptoms

Estal is commonly used in patients with moderate acne to help address skin manifestations and oiliness where symptoms create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview of Oral Contraceptive Pills

Eligibility and Restrictions for Use

The official regulatory documents define Estal's eligibility profile by centering non-eligibility on conditions that pose an unacceptable health risk, primarily thromboembolic risk and hormone-sensitive conditions. The medication is indicated for use in females after menarche for its labeled purposes of contraception or moderate acne treatment.


Key Eligibility Statuses

Status Population Restrictions
Absolute Contraindicated Pregnancy is prohibited. Contraindications include a history of arterial or venous thrombotic events (e.g., DVT, stroke), known thrombogenic mutations, active or historical malignant hormone-sensitive tumours, and current liver tumours or severe liver function disorders.
Conditional Prohibition Use is strictly contraindicated for women over 35 years of age who smoke. Other prohibitions apply to patients with uncontrolled hypertension or uncontrolled diabetes mellitus with vascular symptoms. Concomitant use with specific Hepatitis C regimens is also prohibited.
Not Recommended Breastfeeding women should not use this medication as officially documented.

What should I know about interactions with other medicines?

Estal (exemestane) may interact with certain other medicines and products, which can affect its effectiveness or alter the effects of the co-administered drug.

Interactions that Decrease Estal Effectiveness

The simultaneous use of Estal with certain medicines known as potent CYP3A4 enzyme inducers may significantly reduce the amount of Estal in the body. This reduction can lead to lower effectiveness of the treatment. Medicines that fall into this category include certain anticonvulsants, such as phenytoin and carbamazepine, and the anti-tuberculosis medicine rifampicin. The herbal preparation St. John’s Wort (Hypericum perforatum) is also a potent inducer and should not be used with Estal.

Contraindicated Combination

Estal must not be used together with oestrogen-containing medicines or hormone replacement therapy. Since Estal works by significantly lowering oestrogen levels, taking oestrogen products would directly counteract its intended action, making the treatment ineffective.

General Precautions

Because Estal is processed in the body by the CYP3A4 enzyme, caution is necessary when co-administering it with other medicines that are also broken down by this enzyme and have a narrow therapeutic window. Patients should always inform their healthcare provider about all prescription drugs, non-prescription medicines, herbal products, and supplements they are taking to manage potential interactions safely.

Mechanism of Action

Estal functions primarily as a selective histamine H1-receptor antagonist. It exhibits a high-affinity competitive binding interaction at the H1-receptor located on the surface of various cell types. The antagonism prevents the binding of endogenous histamine to the receptor. Intracellularly, this blockade inhibits the histamine-mediated cascade, which typically involves increased permeability of vascular endothelium and local cellular activation. Estal also acts as a mast cell stabilizer, inhibiting the intracellular release of inflammatory mediators such as histamine, tryptase, and leukotrienes following cell degranulation stimuli. The downstream systemic consequence is a generalized modulation of inflammatory signaling pathways, leading to a diminished local physiological response.

Dosage and Administration Information

Instruction Map: How to use Estal — Administration Guidelines

Estal is administered exclusively by the oral route as a monophasic film-coated tablet, following standardized, daily dosing schedules.

Instruction Detail
Route of administration Oral route only.
Dosing schedule One tablet daily; regimens are cyclic (e.g., 21/7 or 24/4) with active doses typically containing 2 mg Chlormadinone acetate and either 0.02 mg or 0.03 mg Ethinyl Estradiol.
Timing in relation to meals May be administered without regard to meals.
Special procedural conditions Tablets must be taken at approximately the same time each day and in the exact sequence directed on the blister packaging.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily and Cyclic (28-day cycle)
Use-context constraints Efficacy has not been evaluated or confirmed in women with a Body Mass Index (BMI) greater than 35 kg/m^2.

Resulting Procedural Structure

Step sequence:

  • The protocol requires the daily intake of one active tablet for the prescribed duration (21 or 24 days) followed by the specific break period (7 or 4 days, respectively).
  • The regimen requires adherence to specialized management protocols if a tablet is missed or if a severe gastrointestinal event (vomiting/diarrhea) occurs within 3 to 4 hours of active dose intake.

Connection to the overall use protocol: This set of instructions defines a highly formalized, 28-day continuous, cyclic protocol for the medicine's administration. The rigid requirements for daily timing and sequential intake are fundamental to maintaining the intended systemic dosing pattern. The inclusion of specific procedures for handling missed tablets ensures a standardized response to interruptions in the daily regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Estal


Research Evidence for Contraception and Pregnancy Prevention

The research basis for Estal (Chlormadinone acetate / Ethinyl Estradiol) in pregnancy prevention primarily involves large randomized controlled trials (RCTs) and comprehensive systematic reviews relied upon by regulatory bodies. These studies have primarily focused on examining the mechanisms and results of the medication's intended function (contraception). Researchers measured contraceptive effectiveness, commonly using the Pearl Index, which describes the number of unintended pregnancies per 100 woman-years of use. Studies also monitored the consistency and stability of hormonal control.

Studies reported measurements where, among women in the study populations, measurements of the Pearl Index were consistently reported across trials. Research describes the patterns of cycle regulation observed in study participants, which is the expected outcome related to hormonal suppression of ovulation. Research has explored the medication's role in the hormonal mechanisms studied for systemic avoidance of pregnancy.


Research Evidence for Moderate Acne and Skin Symptoms

The evidence for using Estal in the context of moderate acne vulgaris comes from short-term to intermediate-term randomized controlled trials (RCTs). The research basis for the medication's components includes placebo-controlled studies examining the measured changes in moderate acne. Studies report how symptoms evolved in the observed populations, noting changes in the lesion count—both the number of inflamed lesions and non-inflamed lesions.

Findings describe measured changes in both types of lesions over the intermediate follow-up duration. Data also show patterns related to an association between the medication's use and measured changes in symptoms of skin oiliness (seborrhea), which is a key outcome linked to inflammatory or irritative states.


Evidence Gaps and Areas of Uncertainty

Research exploring long-term outcomes primarily consists of data from observational settings across the indications. Follow-up durations were limited in many studies evaluating acne and symptom relief, meaning there is limited information for long-term outcomes on sustained change beyond 6 to 12 months. Data for certain groups remain insufficient, particularly for women with specific complex comorbidities where the interaction with the medication has not been the central focus of major trials.

Key Studies & References Oral Contraceptive Pills (OCPs)

Frequently Asked Questions (FAQ)

Common questions about Estal (FAQ)


Q: Is Estal considered a high-risk medication?

Official product information states that Estal belongs to the class of Combined Hormonal Contraceptives (CHCs). This class is associated with known risks, most significantly Venous Thromboembolism (VTE) and Arterial Thromboembolism (ATE), which are considered medically serious adverse events. These are part of the officially documented safety profile.


Q: How does Estal compare to similar medicines I see advertised?

Estal contains the active ingredients Chlormadinone acetate and Ethinyl Estradiol. The Chlormadinone acetate component is a progestogen with acknowledged anti-androgenic properties. This specific profile is often noted as a differentiating feature when comparing it neutrally to some other Combined Oral Contraceptives.


Q: Will Estal interact with common pain relievers?

Regulatory documents primarily list interactions that could affect Estal's effectiveness, such as with potent CYP3A4 enzyme inducers. Common non-prescription pain relievers are generally not specifically listed among the medications that pose a major risk of interaction or diminished efficacy in regulatory summaries.


Q: Are there any major diet restrictions while taking Estal?

According to official guidelines, Estal may be taken without regard to meals (e.g., on an empty stomach or with food). The regulatory information provided does not list major dietary restrictions beyond standard cautions regarding medication interactions.


Q: Can people over 65 use Estal?

Estal is indicated for purposes such as contraception and moderate acne treatment in women after menarche. Its use is aligned with the reproductive years, and it is not typically specified or evaluated for use in post-menopausal or elderly populations (over 65).


Q: What are the official approvals for Estal in different countries?

The active components of Estal, Chlormadinone acetate and Ethinyl Estradiol, are recognized and approved for their labeled indications by major health authorities. For example, the drug's classification and use are reviewed and accepted by bodies like the European Medicines Agency (EMA).


Q: Can Estal be used long-term?

While Estal is intended for continuous, long-term contraception, research overviews indicate there may be limited long-term safety data for specific outcomes in some study populations beyond 6 to 12 months. Decisions regarding continuous long-term use are guided by individual health status and regulatory standards.


Q: What should I know about Estal if I am planning a pregnancy?

Regulatory documents establish that Estal is strictly contraindicated (prohibited) if you are already pregnant. Official guidance often states that fertility typically returns shortly after stopping a Combined Oral Contraceptive.


Q: What is the intended duration of use for Estal?

Estal is intended for daily and continuous use as a contraceptive, following a precise, cyclic dosing regimen. The official intended use is continuous, daily administration, and the overall duration of treatment is guided by individual health status and indication needs.


Q: What is the experience of patients described in research trials of Estal?

Research trials describe measurable, objective outcomes, such as a consistent Pearl Index for efficacy and a reduction in acne lesion count. The studies also document the patterns of cycle regulation and the frequency of side effects that were observed across patient populations.


Q: How do the benefits of Estal outweigh the risks, according to regulatory data?

Regulatory bodies review the collected research and safety data to determine the drug's risk/benefit profile. Official approval is granted because these bodies conclude that the benefits outweigh the risks when the medication is used strictly according to the official label and risk mitigation criteria.


Q: Can Estal be split or crushed?

Estal is manufactured as an oral film-coated tablet. According to standard regulatory guidance for this dosage form, the tablet is designed not to be crushed, split, or chewed. This ensures the integrity of the active dosage and the intended way the medicine is absorbed.


Q: Do the effects of Estal diminish over time?

Research summaries indicate that trials primarily focused on short- to intermediate-term outcomes, meaning that sustained changes beyond 6 to 12 months were not the central focus of major studies. However, the efficacy for contraception is supported by long-term data gathered from observational settings.


Q: Can Estal affect my ability to drive?

Official product labels do not commonly list effects like severe dizziness or extreme somnolence that would directly impair a person's ability to drive or operate machinery. Regulatory information suggests that individuals should be aware of any effects the medicine may have on their concentration, particularly when initiating treatment.


Q: How long does it typically take to feel any effects from Estal?

When started on the first day or within the first five days of the menstrual cycle, contraceptive protection usually begins immediately. If started at any other time, official guidelines recommend that other protective methods be used until seven consecutive days of active tablets have been taken to establish reliable protection.


Q: How long do the effects of Estal last after I take a dose?

Estal is designed as a daily medicine to maintain steady levels of hormones in the body. The progestogen component, Chlormadinone acetate, has an estimated half-life of approximately 38 hours, which supports the need for consistent, once-daily dosing.


Q: Does Estal affect sleep?

Although not always specifically listed for Estal, regulatory safety literature for similar hormonal contraceptives has noted the potential for effects such as trouble sleeping (insomnia) or feelings of tiredness. These are possible effects that may occur, as reported in various studies.


Q: What is the primary way Estal is eliminated from the body?

According to the official pharmacokinetic data, the active components of Estal are first metabolized, primarily in the liver. They are then eliminated from the body through a combination of processes that involve excretion in both the urine and the feces.

How should Estal be stored and disposed of?

Storage Conditions

Estal tablets must be stored according to official regulatory labeling to maintain stability. The medicine must be kept at room temperature, generally defined as not exceeding 30 C (86 F). It is mandatory to keep the tablets in the original blister pack and outer carton to protect them from both light and moisture. The product should not be refrigerated or frozen. Do not use the medication past the expiry date (EXP) indicated on the packaging.

Child Safety and Disposal

For safety, the medication must be stored out of the sight and reach of children. Disposal of unused or expired Estal must be managed through official channels. Do not dispose of the tablets via wastewater (i.e., flushing) or household trash. Patients should use a drug take-back program or consult a pharmacist for guidance on local pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estal found in:

A-Z Index: